Results 21 to 30 of about 4,918,610 (234)
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation [PDF]
, 2023 Background Oral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation require dose adjustment based on certain clinical criteria, but the off-label use of the reduced doses is common. Methods
Marsch, Armin +9 more
core +2 more sources
Thrombocytopenia induced by dabigatran: two case reports
BMC Neurology, 2017 Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke).
Hyun Goo Kang +3 more
doaj +1 more source
Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity. [PDF]
PLoS ONE, 2012 Islet and hepatocyte transplantation are associated with tissue factor-dependent activation of coagulation which elicits instant blood mediated inflammatory reaction, thereby contributing to a low rate of engraftment.
Xavier Stephenne +7 more
doaj +1 more source
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
Journal of Arrhythmia, 2016 The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used.
Yosuke Miwa +5 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Background Inhibition of activated factor XI (FXIa) is a promising antithrombotic drug target. BMS‐724296 is a selective, reversible, small‐molecule inhibitor of human FXIa (Ki 0.3 nM). Objectives This study assessed effects of BMS‐724296 versus standard‐
Pancras C. Wong, Mimi L. Quan
doaj +1 more source
Molecular modeling study of protein-tyrosine kinases and Factor Xa for rational inhibitor design.
, 1999 Molecular modeling study of protein-tyrosine kinases and Factor Xa for rational inhibitor ...
Yasheen. Zhou (7979243)
core +3 more sources
PRISMA XA Checklist and Diagram
, 2021 Prisma Checklist for Factor Xa Inhibitor For Venous Thromboembolism Management In Patient With Cancer: A Sysytematic Review And Meta ...
Makhyan Jibril Al Farabi (7840016)
core +1 more source
Avances en el tratamiento del tromboembolismo pulmonar agudo [PDF]
Revista SOCAMPAR, 2017 Resume: We present a case of a 78-year-old male patient with a personal history of urothelial carcinoma, squamous cell carci- noma of the larynx and colon adenocarcinoma, who came to the emergency room because for about 3 months he had cough with ...
Peña Durán A
doaj
Journal of Arrhythmia, 2016 Background: Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine coagulation monitoring, high-risk patients require monitoring to assess pharmacodynamics.
Kozue Ikeda, MD, Hideaki Tachibana, MD
doaj +1 more source
Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity [PDF]
, 1998 Tissue factor : factor VIIa induced activation of blood coagulation is inhibited by the complex between factor Xa and tissue factor pathway inhibitor (factor Xa : TFPI).
Hemker, H. Coenraad +13 more
core +1 more source